已收盤 04-11 16:00:00 美东时间
0.000
0.00%
Kalaris Therapeutics announced that clinical data from its Phase 1 study of TH103, a novel therapy targeting VEGF and HSPG, will be presented at the 49th Macula Society Annual Meeting. The presentation, "First-in-Human Evaluation of TH103," will highlight safety, tolerability, pharmacokinetics, and early efficacy in treatment-naive neovascular AMD. Dean Eliott, MD, will present on February 26, 2026, in San Diego. Kalaris, founded by VEGF pioneer ...
01-28 21:05
Shares of Neovasc Inc. (NASDAQ:NVCN – Get Rating) (TSE:NVC) passed above its 50...
2023-04-27 18:00
StockNews.com began coverage on shares of Neovasc (NASDAQ:NVCN – Get Rating) (T...
2023-04-06 16:02
Alpha Tau Medical (NASDAQ:DRTS – Get Rating) and Neovasc (NASDAQ:NVCN – Get Rat...
2023-03-09 15:44
Neovasc (NASDAQ:NVCN – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Ratin...
2023-03-01 17:53
Neovasc Inc. (NASDAQ:NVCN – Get Rating) (TSE:NVC) was the target of a large inc...
2023-02-11 13:28
IRadimed (NASDAQ:IRMD – Get Rating) and Neovasc (NASDAQ:NVCN – Get Rating) are ...
2023-01-22 14:21
Bloom Burton lowered shares of Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) fro...
2023-01-21 15:31
Neovasc (TSE:NVC – Get Rating) (NASDAQ:NVCN) was downgraded by investment analy...
2023-01-20 16:42
StockNews.com began coverage on shares of Neovasc (NASDAQ:NVCN – Get Rating) (T...
2023-01-16 16:31